Showing results (121-130 of 219) with videos related to

Sort By:
Pageof 22
Cancer Chemotherapy and Pharmacology|May 4, 2023
Phase I study of the VEGF/Ang-2 inhibitor BI 836880 alone or combined with the anti-programmed cell death protein-1 antibody ezabenlimab in Japanese patients with advanced solid tumorsNoboru Yamamoto, Takafumi Koyama, Toshio Shimizu, et al.
Cancer Chemotherapy and Pharmacology|November 21, 2019
Improved survival among patients enrolled in oncology phase 1 trials in recent decadesTakahiro Ebata, Toshio Shimizu, Takafumi Koyama, et al.
The Journal of Organic Chemistry|December 8, 2020
Reduction of Ethynylenes to Vinylenes in a Macrocyclic π-Extended Thiophene Skeleton Under McMurry Coupling ConditionsKeigo Shirahata, Masataka Takashika, Kazunori Hirabayashi, et al.
Cancer Chemotherapy and Pharmacology|July 12, 2018
An early clinical trial of Salirasib, an oral RAS inhibitor, in Japanese patients with relapsed/refractory solid tumorsJunji Furuse, Takayasu Kurata, Naohiro Okano, et al.
Japanese Journal of Clinical Oncology|April 12, 2007
Concurrent chemoradiotherapy for limited-disease small cell lung cancer in elderly patients aged 75 years or olderToshio Shimizu, Ikuo Sekine, Minako Sumi, et al.
Cancer Medicine|March 6, 2021
Phase 1 study of telisotuzumab vedotin in Japanese patients with advanced solid tumorsYutaka Fujiwara, Hirotsugu Kenmotsu, Noboru Yamamoto, et al.
Rinsho Shinkeigaku = Clinical Neurology|December 3, 2013
[Amyotrophic lateral sclerosis in totally locked-in state]Kiyomitsu Oyanagi, Yoko Mochizuki, Yuki Nakayama, et al.
Cancer Chemotherapy and Pharmacology|June 28, 2007
Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumorsToshio Shimizu, Noboru Yamamoto, Yasuhide Yamada, et al.
Clinical Neuropathology|June 5, 2015
Marked preservation of the visual and olfactory pathways in ALS patients in a totally locked-in stateKiyomitsu Oyanagi, Yoko Mochizuki, Yuki Nakayama, et al.
Anticancer Research|March 10, 2015
Circulating hepatocyte growth factor is correlated with resistance to cetuximab in metastatic colorectal cancerKimio Yonesaka, Taroh Satoh, Shinya Ueda, et al.
Pageof 22